COMMUNIQUÉS West-GlobeNewswire
-
OKYO Pharma Announces Chairman and Founder Acquires Shares
19/03/2026 -
New partnership to fast-track Canadian health technology from innovation to patient care
19/03/2026 -
Fangzhou Reports Robust 2025 Financial Results, Boosted by AI Chronic Care Strategy
19/03/2026 -
Backpage Sex Trafficking Survivors Break Silence, Demand Investigation of Uncharged Enablers as Compensation Deadline Approaches
19/03/2026 -
The Endothelial Glycocalyx Explained: How It Helps Regulate Vascular Function
19/03/2026 -
SK pharmteco réaffirme sa stratégie à trois unités d’activité et renforce son pôle mondial de thérapie génique grâce à un engagement de financement
19/03/2026 -
NMDP Celebrates Bipartisan Senate Introduction of Life-saving Blood Stem Cell Therapeutic and Research Reauthorization Act
19/03/2026 -
Novo Nordisk A/S: Wegovy® HD (semaglutide 7.2 mg) approved in the US, providing 20.7% mean weight loss
19/03/2026 -
OKYO Pharma Announces Director Acquires Shares
19/03/2026 -
Passing of Genmab A/S’ Annual General Meeting
19/03/2026 -
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
19/03/2026 -
Aclarion, Inc. Adopts Limited Duration Stockholder Rights Plan
19/03/2026 -
Evermore Expands Community Health Access in Ohio Through New Partnership with Discount Drug Mart
19/03/2026 -
Notice to convene Evaxion’s Annual General Meeting
19/03/2026 -
CORRECTION: Lucia Gaitan, M.D., FACOG, First in Miami to Offer Cerene® Endometrial Cryotherapy for Women with Heavy Periods
19/03/2026 -
Diadia Launches AI Platform to Finally Give Women Answers to "Unexplained" Health Problems
19/03/2026 -
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
19/03/2026 -
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
19/03/2026 -
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
Pages